Nehad Soloman, MD, FACR

Nehad Soloman, MD, comments on the use of precision medicine and its advantages in the field of rheumatology.

An expert in rheumatology shares updates in clinical research that may shape rheumatic disease care in the future.

Drs Nehad Soloman, Joy Schechtman, and Robert Levine share insights on how to measure treatment efficacy in the management of RA.

Rheumatology experts discuss the potential roadblocks to treatment of RA, such as insurance access.

Dr Nehad Soloman provides insight on recent approvals and upcoming FDA submissions in biosimilars, including for lupus nephritis, and how they may change the course of rheumatic disease management moving forward.

Nehad Soloman, MD, discusses the impact of new biosimilars to become available in the U.S. in 2023 on rheumatic disease management.

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levine, MD, review how the increase in treatment options for RA has led to a trial-and-error approach to treatment.

Drs Nehad Soloman, Joy Schechtman, and Robert Levine describe the treatment path from conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to biologic or targeted disease-modifying antirheumatic drugs (b/tsDMARDs) for a typical rheumatoid arthritis (RA) patient.